SRRK — Scholar Rock Holding Corporation

Scholar Rock Holding Corporation (SRRK) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Operating Expenses: Q4 2025 operating expenses totaled $91.9 million, including $19.4 million in non-cash stock-based compensation. Excluding this, operating expenses were $72.5 million. For the full year 2025, total operating expenses were $384.6 million ($309 million excluding stock-based compensation).
• Cash Position: Ended 2025 with $368 million in cash and cash equivalents, bolstered by $60.4 million from warrant exercises.
• Debt Facility: Secured a new debt facility for up to $550 million, with immediate access to $100 million and additional funds contingent on FDA approval of their lead product.

2. Strategic Updates and Business Highlights

• Product Development: Focus remains on bringing upitigramab, a muscle-targeted therapy for Spinal Muscular Atrophy (SMA), to market. The company is prepared for a Biologics License Application (BLA) resubmission following a successful FDA reinspection of the Catalent facility.
• Regulatory Engagement: Positive interactions with the FDA, including a recent meeting where no additional requests were made regarding the remediation plan for the manufacturing facility.
• Commercial Readiness: The U.S. commercial team is actively engaging with prescribers and payers, with plans for a launch in the second half of 2026. Preparations include expanding specialty pharmacy networks and establishing patient support programs.

3. Forward Guidance and Outlook

• BLA Resubmission: The company reaffirms guidance for BLA resubmission and U.S. launch in 2026, contingent on successful reinspection of the manufacturing facility.
• European Market: Anticipates a decision from the European Medicines Agency (EMA) regarding the Marketing Authorization Application (MAA) in mid-2026.
• Pipeline Development: Plans to initiate a Phase 2 study for upitigramab in Facioscapulohumeral Muscular Dystrophy (FSHD) later in 2026, alongside ongoing studies for other myostatin inhibitors.

4. Bad News, Challenges, or Points of Concern

• Regulatory Risks: The approval timeline is contingent on the successful reinspection of the Catalent facility, which poses a risk if issues arise.
• Market Competition: The SMA treatment landscape is evolving, with existing SMN-targeted therapies already in use, which may affect the uptake of upitigramab.
• Financial Sustainability: While current cash reserves are strong, ongoing investments in R&D and commercial readiness raise questions about the timeline to profitability and potential future financing needs.

5. Notable Q&A Insights

• FDA Reinspection: Management expressed confidence in the upcoming reinspection, indicating that a successful outcome would trigger the BLA resubmission promptly.
• Label Expectations: There is optimism regarding the potential for a broad label for upitigramab, with previous discussions with the FDA suggesting a favorable outcome based on existing clinical data.
• Market Readiness: The commercial team is tracking engagement with payers and physicians, noting that while there is robust demand for the new therapy, initial access challenges may arise post-launch.
• Enrollment Trends: Positive enrollment trends in clinical trials indicate strong interest and awareness of upitigramab within the SMA community, suggesting readiness for market entry.

Overall, Scholar Rock is positioned for a transformative year in 2026, with significant focus on regulatory approvals and market readiness for its lead product while navigating potential challenges in the competitive landscape and regulatory environment.